Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors
about
Low dose versus high dose stavudine for treating people with HIV infectionLow dose versus high dose stavudine for treating people with HIV infectionIn vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsInsulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injuryTenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsTenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trialAn analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitorsTenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*Synthesis and characterization of azo-guanidine based alcoholic media naked eye DNA sensorBiological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesGetting to 90-90-90 in paediatric HIV: What is needed?In vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration.Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.Tenofovir-associated bone density loss.Abacavir/lamivudine combination in the treatment of HIV: a review.Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infantsMechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosineMeasurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patientsA Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.Antiretroviral therapy in the clinicIncomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposureAccumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitorsPossible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIVAging, human immunodeficiency virus, and bone health.In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionPre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases.Tenofovir disoproxil fumarate.Reducing plasma HIV RNA improves muscle amino acid metabolism.Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.Tenofovir disoproxil fumarate for the treatment of HIV infection.Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis BEvaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion.A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.
P2860
Q24186488-1522C3EF-9F82-493A-86E9-683ECD2B6EA8Q24242088-56C83ED2-7000-4DC2-8A57-8EA6A7A88097Q24674939-5078A8CB-03E5-425D-A3A0-E1BF4FDDB560Q24802256-94FC5FE6-A348-40D2-82D2-F61BC6E14CF2Q26995852-894A4EC4-7BC5-48E2-87B2-C6D68724558DQ28088839-907E220E-284F-4CA0-88D6-1DA0328E4F7EQ28469218-F568F4D6-0D81-44A8-803F-811E4334101CQ28474361-6A03F5C4-973F-4CF4-88CE-FCFA83BC17E1Q28571788-8780EDFE-8132-4B9D-9ABD-6769A7C9DEE3Q28585042-0F2F6478-1F6F-4833-A275-0919732DD559Q28775900-798D4920-ECB1-4B54-BF80-2CAD889CA583Q30385352-663C4B33-5FAD-4058-8252-79861C75E8A5Q30885827-A1C93B72-EA9F-4464-9973-212DB90BCDFBQ31050092-71B2766A-5E04-4905-B9E9-CD104CD55456Q33381965-456349A1-C710-492A-B2A7-DCE8CAC81BF6Q33635034-83C86E3B-1A3A-46F9-AAAD-DEF44072AA98Q33715435-FF4DA74B-9CC3-4FE6-8C96-CD1811CD4889Q33747993-EE444D94-8944-45EB-B4AB-83F0550EA294Q33769970-63E5C697-8AC3-4EE0-8F20-8497270CDDE2Q33770032-FF933522-BD6A-42E3-B45B-4E19A55599B5Q33819098-27D11246-5235-49DC-816A-7DA86042B1EEQ33877347-5C574439-6EC3-48F2-8CFD-696D06BA133EQ33880241-4361BF5A-5B0D-4DF0-9959-10955D3572B2Q33904479-B96517F8-D5A5-41F1-AEEA-10ABCD2DC510Q34036150-26BC7885-7E75-46FC-B3EA-958AF5F983C7Q34160511-0EF77571-40ED-4FFB-8149-4DF54391E16EQ34289964-DCE2D76A-AE12-48E0-820D-CB6AA5917AD9Q34371989-CA17AE55-7F4B-4C18-97D6-4139A4F863C7Q34409132-8B4E77E6-76C1-4CE3-A9F7-2785260EB578Q34481359-9B56E45F-B912-4F9E-B7C6-B3E562866CCDQ34483566-7CA7F1C4-D9FA-47F1-ACD7-AF8EE3D4E8ABQ34534058-C299D7F0-EBFA-4FB0-BF48-E1CE53728AD8Q34550863-B5A5FE03-4E51-4436-ADDC-ACBF45C2937FQ34551836-9AE17121-00DF-47CF-B7D6-9AB10DFC895CQ34569309-41F70160-9EEC-40CD-8202-F1E0C79CF099Q34591879-9332857D-6199-4BA4-86C4-C5248344636FQ34932672-E115B3C7-DF03-45A3-A158-02AAFBAAE475Q35043368-8713D28D-1747-4AAA-A939-33871A4323BFQ35049863-27C5A08B-022A-456A-9339-731BBC35AFD1Q35149475-1894AF67-DCE2-4E77-A685-59B811860E92
P2860
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@ast
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@en
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@nl
type
label
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@ast
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@en
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@nl
prefLabel
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@ast
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@en
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@nl
P2093
P2860
P1476
Assessment of mitochondrial to ...... verse transcriptase inhibitors
@en
P2093
Gabriel Birkus
Michael J M Hitchcock
Tomas Cihlar
P2860
P304
P356
10.1128/AAC.46.3.716-723.2002
P407
P577
2002-03-01T00:00:00Z